Who
Nerissa Kreher
Director
Company insider
Files Form 4 as: Director, Xeris Biopharma Holdings; Director, Rezolute; Chief Medical Officer, Entrada Therapeutics; Chief Medical Officer, Tectonic Therapeutic.
In numbers
- Trades disclosed
- 81
- Buys
- 1
- Sells
- 16
- Bought
- $9,997
- Sold
- $998K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 8 Oct 2018
- Last trade
- 1 Jul 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —33,582 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $303K37,910 at $8.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $303K37,910 at $8.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —33,582 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 13 Jun 2025filed 23 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $9,9973,076 at $3.25 | filing |
| 10 Jun 2025filed 13 Jun 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 10 Jun 2025filed 13 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Sep 2023filed 6 Sep 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K871 at $13.46 | filing |
| 6 Sep 2023filed 6 Sep 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $29421 at $14.00 | filing |
| 5 Sep 2023filed 6 Sep 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,798401 at $14.46 | filing |
| 1 Sep 2023filed 6 Sep 2023 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 1 Sep 2023filed 6 Sep 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,200 at $0.00 | filing |
| 4 Aug 2023filed 4 Aug 2023 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,898 at $0.00 | filing |
| 4 Aug 2023filed 4 Aug 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code M | $14K6,898 at $2.10 | filing |
| 4 Aug 2023filed 4 Aug 2023 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K6,898 at $14.14 | filing |
News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Nerissa Kreher; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.